Review



sch442416 2 2 furanyl  (Tocris)


Bioz Verified Symbol Tocris is a verified supplier
Bioz Manufacturer Symbol Tocris manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Tocris sch442416 2 2 furanyl
    Figure 3. The analgesic effect of FBP on CCI-induced mechanical hyperalgesia is dependent on adenosine A1 and A2 receptors. (A) Schematic representation of experimental design in this figure; (B) Treatment with DPCPX (A1 receptor antagonist) via i.t. route; (C) Treatment with DPCPX (A1 receptor antagonist) via i.pl. route; (D) Treatment with <t>SCH442416</t> (A2A receptor antagonist) via i.t. route; (E) Treatment with SCH442416 (A2A receptor antagonist) via i.pl. route. n = 5–6 mice per group per experiment. * p < 0.05 CCI vs. sham group; # p < 0.05 vs. CCI + vehicle group; ** p < 0.05 vs. CCI + FBP 300 mg/kg group. *** p < 0.05 vs. vehicle group and CCI + FBP 300 mg/kg group (Two-way ANOVA followed by Tukey’s post-test).
    Sch442416 2 2 Furanyl, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 72 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sch442416 2 2 furanyl/product/Tocris
    Average 93 stars, based on 72 article reviews
    sch442416 2 2 furanyl - by Bioz Stars, 2026-06
    93/100 stars

    Images

    1) Product Images from "Fructose-1,6-Bisphosphate Reduces Chronic Constriction Injury Neuropathic Pain in Mice by Targeting Dorsal Root Ganglia Nociceptive Neuron Activation"

    Article Title: Fructose-1,6-Bisphosphate Reduces Chronic Constriction Injury Neuropathic Pain in Mice by Targeting Dorsal Root Ganglia Nociceptive Neuron Activation

    Journal: Pharmaceuticals

    doi: 10.3390/ph18050660

    Figure 3. The analgesic effect of FBP on CCI-induced mechanical hyperalgesia is dependent on adenosine A1 and A2 receptors. (A) Schematic representation of experimental design in this figure; (B) Treatment with DPCPX (A1 receptor antagonist) via i.t. route; (C) Treatment with DPCPX (A1 receptor antagonist) via i.pl. route; (D) Treatment with SCH442416 (A2A receptor antagonist) via i.t. route; (E) Treatment with SCH442416 (A2A receptor antagonist) via i.pl. route. n = 5–6 mice per group per experiment. * p < 0.05 CCI vs. sham group; # p < 0.05 vs. CCI + vehicle group; ** p < 0.05 vs. CCI + FBP 300 mg/kg group. *** p < 0.05 vs. vehicle group and CCI + FBP 300 mg/kg group (Two-way ANOVA followed by Tukey’s post-test).
    Figure Legend Snippet: Figure 3. The analgesic effect of FBP on CCI-induced mechanical hyperalgesia is dependent on adenosine A1 and A2 receptors. (A) Schematic representation of experimental design in this figure; (B) Treatment with DPCPX (A1 receptor antagonist) via i.t. route; (C) Treatment with DPCPX (A1 receptor antagonist) via i.pl. route; (D) Treatment with SCH442416 (A2A receptor antagonist) via i.t. route; (E) Treatment with SCH442416 (A2A receptor antagonist) via i.pl. route. n = 5–6 mice per group per experiment. * p < 0.05 CCI vs. sham group; # p < 0.05 vs. CCI + vehicle group; ** p < 0.05 vs. CCI + FBP 300 mg/kg group. *** p < 0.05 vs. vehicle group and CCI + FBP 300 mg/kg group (Two-way ANOVA followed by Tukey’s post-test).

    Techniques Used:



    Similar Products

    92
    MedChemExpress sch 442416
    Sch 442416, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sch 442416/product/MedChemExpress
    Average 92 stars, based on 1 article reviews
    sch 442416 - by Bioz Stars, 2026-06
    92/100 stars
      Buy from Supplier

    93
    Tocris sch442416 2 2 furanyl
    Figure 3. The analgesic effect of FBP on CCI-induced mechanical hyperalgesia is dependent on adenosine A1 and A2 receptors. (A) Schematic representation of experimental design in this figure; (B) Treatment with DPCPX (A1 receptor antagonist) via i.t. route; (C) Treatment with DPCPX (A1 receptor antagonist) via i.pl. route; (D) Treatment with <t>SCH442416</t> (A2A receptor antagonist) via i.t. route; (E) Treatment with SCH442416 (A2A receptor antagonist) via i.pl. route. n = 5–6 mice per group per experiment. * p < 0.05 CCI vs. sham group; # p < 0.05 vs. CCI + vehicle group; ** p < 0.05 vs. CCI + FBP 300 mg/kg group. *** p < 0.05 vs. vehicle group and CCI + FBP 300 mg/kg group (Two-way ANOVA followed by Tukey’s post-test).
    Sch442416 2 2 Furanyl, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sch442416 2 2 furanyl/product/Tocris
    Average 93 stars, based on 1 article reviews
    sch442416 2 2 furanyl - by Bioz Stars, 2026-06
    93/100 stars
      Buy from Supplier

    93
    Tocris sch442416
    Fig. 5 A2A mediates FAO through regulating CPT1A expression. (A-B) Immunoblot analysis of CPT1A (A) and RT-qPCR analysis of CPT1A (B) in dermal fibroblasts treated with TGF-β, with or without 1–20 μM <t>SCH442416,</t> for 48 h. (C-D) Representative immunofluorescent staining of CPT1A (green) and VI MENTIN (red) (C), and quantification of VIMENTIN+ CPT1A+ cells in the skin tissues from HC and SSc patients (D) (n = 5, scale bar: 20 μm). (E-F) Immunoblot analysis of fibronectin and α-SMA (E), and RT-qPCR analysis of COL1A1, COL1A2 and FN1 mRNA (F), in dermal fibroblasts treated with TGF-β, SCH442416 <t>(10μM),</t> and etomoxir (5μM) for 48 h. (G) RT-qPCR analysis of CPT1A mRNA in dermal fibroblasts after silencing of CPT1A. (H-I) Immunoblot analysis of fibronectin, α-SMA and CPT1A (H), and RT-qPCR analysis of ACTA2 and FN1 mRNA (I), in dermal fibroblasts after silencing of CPT1A and incubation with TGF-β for 48 h. (J-K) Immunoblot analysis of fibronectin and α-SMA (J), and RT-qPCR analysis of ACTA2 and FN1 mRNA (K), in dermal fibroblasts after silenc ing of CPT1A and incubation with TGF-β and SCH442416 (10μM) for 48 h. RT-qPCR results were normalized against GAPDH. Error bars represent mean +/- SD range. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001; HC, healthy control
    Sch442416, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sch442416/product/Tocris
    Average 93 stars, based on 1 article reviews
    sch442416 - by Bioz Stars, 2026-06
    93/100 stars
      Buy from Supplier

    92
    MedChemExpress hy 103169
    Fig. 5 A2A mediates FAO through regulating CPT1A expression. (A-B) Immunoblot analysis of CPT1A (A) and RT-qPCR analysis of CPT1A (B) in dermal fibroblasts treated with TGF-β, with or without 1–20 μM <t>SCH442416,</t> for 48 h. (C-D) Representative immunofluorescent staining of CPT1A (green) and VI MENTIN (red) (C), and quantification of VIMENTIN+ CPT1A+ cells in the skin tissues from HC and SSc patients (D) (n = 5, scale bar: 20 μm). (E-F) Immunoblot analysis of fibronectin and α-SMA (E), and RT-qPCR analysis of COL1A1, COL1A2 and FN1 mRNA (F), in dermal fibroblasts treated with TGF-β, SCH442416 <t>(10μM),</t> and etomoxir (5μM) for 48 h. (G) RT-qPCR analysis of CPT1A mRNA in dermal fibroblasts after silencing of CPT1A. (H-I) Immunoblot analysis of fibronectin, α-SMA and CPT1A (H), and RT-qPCR analysis of ACTA2 and FN1 mRNA (I), in dermal fibroblasts after silencing of CPT1A and incubation with TGF-β for 48 h. (J-K) Immunoblot analysis of fibronectin and α-SMA (J), and RT-qPCR analysis of ACTA2 and FN1 mRNA (K), in dermal fibroblasts after silenc ing of CPT1A and incubation with TGF-β and SCH442416 (10μM) for 48 h. RT-qPCR results were normalized against GAPDH. Error bars represent mean +/- SD range. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001; HC, healthy control
    Hy 103169, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hy 103169/product/MedChemExpress
    Average 92 stars, based on 1 article reviews
    hy 103169 - by Bioz Stars, 2026-06
    92/100 stars
      Buy from Supplier

    86
    MedChemExpress china sch442416 injection
    Schedule of experiment and scoring. A Schematic diagram of the experimental procedure. B Survival curve. C HE staining and Safranin O-fast green staining in each group. D Histological score changes in the L5-6 intervertebral disk. Data represented mean ± SD (n = 4). E BBB scores. Data represented mean ± SD.* P < 0.05 versus S group, † P < 0.05 versus M group, ‡ P < 0.05 versus CGS-21680 group. S, sham operation group; M, IL-1β-induced IDD model group; CGS-21680, A 2A R agonist CGS-21680 group; <t>SCH442416,</t> A 2A R antagonist SCH442416 group
    China Sch442416 Injection, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/china sch442416 injection/product/MedChemExpress
    Average 86 stars, based on 1 article reviews
    china sch442416 injection - by Bioz Stars, 2026-06
    86/100 stars
      Buy from Supplier

    Image Search Results


    Figure 3. The analgesic effect of FBP on CCI-induced mechanical hyperalgesia is dependent on adenosine A1 and A2 receptors. (A) Schematic representation of experimental design in this figure; (B) Treatment with DPCPX (A1 receptor antagonist) via i.t. route; (C) Treatment with DPCPX (A1 receptor antagonist) via i.pl. route; (D) Treatment with SCH442416 (A2A receptor antagonist) via i.t. route; (E) Treatment with SCH442416 (A2A receptor antagonist) via i.pl. route. n = 5–6 mice per group per experiment. * p < 0.05 CCI vs. sham group; # p < 0.05 vs. CCI + vehicle group; ** p < 0.05 vs. CCI + FBP 300 mg/kg group. *** p < 0.05 vs. vehicle group and CCI + FBP 300 mg/kg group (Two-way ANOVA followed by Tukey’s post-test).

    Journal: Pharmaceuticals

    Article Title: Fructose-1,6-Bisphosphate Reduces Chronic Constriction Injury Neuropathic Pain in Mice by Targeting Dorsal Root Ganglia Nociceptive Neuron Activation

    doi: 10.3390/ph18050660

    Figure Lengend Snippet: Figure 3. The analgesic effect of FBP on CCI-induced mechanical hyperalgesia is dependent on adenosine A1 and A2 receptors. (A) Schematic representation of experimental design in this figure; (B) Treatment with DPCPX (A1 receptor antagonist) via i.t. route; (C) Treatment with DPCPX (A1 receptor antagonist) via i.pl. route; (D) Treatment with SCH442416 (A2A receptor antagonist) via i.t. route; (E) Treatment with SCH442416 (A2A receptor antagonist) via i.pl. route. n = 5–6 mice per group per experiment. * p < 0.05 CCI vs. sham group; # p < 0.05 vs. CCI + vehicle group; ** p < 0.05 vs. CCI + FBP 300 mg/kg group. *** p < 0.05 vs. vehicle group and CCI + FBP 300 mg/kg group (Two-way ANOVA followed by Tukey’s post-test).

    Article Snippet: SCH442416 (2-(2-Furanyl)-7-[3-(4-methoxyphenyl)propyl]-7H-pyrazolo [4,3- e][1,2,4]triazolo [1,5-c]pyrimidin-5-amine) and 1,3-dipropyl-8-cyclopentylxanthine (DPCPX, 0439) were obtained from Tocris Cookson (Ballwin, MO, USA).

    Techniques:

    Fig. 5 A2A mediates FAO through regulating CPT1A expression. (A-B) Immunoblot analysis of CPT1A (A) and RT-qPCR analysis of CPT1A (B) in dermal fibroblasts treated with TGF-β, with or without 1–20 μM SCH442416, for 48 h. (C-D) Representative immunofluorescent staining of CPT1A (green) and VI MENTIN (red) (C), and quantification of VIMENTIN+ CPT1A+ cells in the skin tissues from HC and SSc patients (D) (n = 5, scale bar: 20 μm). (E-F) Immunoblot analysis of fibronectin and α-SMA (E), and RT-qPCR analysis of COL1A1, COL1A2 and FN1 mRNA (F), in dermal fibroblasts treated with TGF-β, SCH442416 (10μM), and etomoxir (5μM) for 48 h. (G) RT-qPCR analysis of CPT1A mRNA in dermal fibroblasts after silencing of CPT1A. (H-I) Immunoblot analysis of fibronectin, α-SMA and CPT1A (H), and RT-qPCR analysis of ACTA2 and FN1 mRNA (I), in dermal fibroblasts after silencing of CPT1A and incubation with TGF-β for 48 h. (J-K) Immunoblot analysis of fibronectin and α-SMA (J), and RT-qPCR analysis of ACTA2 and FN1 mRNA (K), in dermal fibroblasts after silenc ing of CPT1A and incubation with TGF-β and SCH442416 (10μM) for 48 h. RT-qPCR results were normalized against GAPDH. Error bars represent mean +/- SD range. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001; HC, healthy control

    Journal: Cell communication and signaling : CCS

    Article Title: Inhibition of adenosine/A2A receptor signaling suppresses dermal fibrosis by enhancing fatty acid oxidation.

    doi: 10.1186/s12964-025-02210-2

    Figure Lengend Snippet: Fig. 5 A2A mediates FAO through regulating CPT1A expression. (A-B) Immunoblot analysis of CPT1A (A) and RT-qPCR analysis of CPT1A (B) in dermal fibroblasts treated with TGF-β, with or without 1–20 μM SCH442416, for 48 h. (C-D) Representative immunofluorescent staining of CPT1A (green) and VI MENTIN (red) (C), and quantification of VIMENTIN+ CPT1A+ cells in the skin tissues from HC and SSc patients (D) (n = 5, scale bar: 20 μm). (E-F) Immunoblot analysis of fibronectin and α-SMA (E), and RT-qPCR analysis of COL1A1, COL1A2 and FN1 mRNA (F), in dermal fibroblasts treated with TGF-β, SCH442416 (10μM), and etomoxir (5μM) for 48 h. (G) RT-qPCR analysis of CPT1A mRNA in dermal fibroblasts after silencing of CPT1A. (H-I) Immunoblot analysis of fibronectin, α-SMA and CPT1A (H), and RT-qPCR analysis of ACTA2 and FN1 mRNA (I), in dermal fibroblasts after silencing of CPT1A and incubation with TGF-β for 48 h. (J-K) Immunoblot analysis of fibronectin and α-SMA (J), and RT-qPCR analysis of ACTA2 and FN1 mRNA (K), in dermal fibroblasts after silenc ing of CPT1A and incubation with TGF-β and SCH442416 (10μM) for 48 h. RT-qPCR results were normalized against GAPDH. Error bars represent mean +/- SD range. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001; HC, healthy control

    Article Snippet: For primary dermal fibroblasts treatment, cells were first starved in serum-free medium containing 0.1% FBS for 16 h, then treated with the following reagents as specified in each experiment, unless stated otherwise: TGF-β (10ng/ml, Peprotech, 100 −21), IL-1β (20 ng/ml, Peprotech, 200-01B), IL-4 (20 ng/ml, Peprotech, 200-04), IL-6 (20 ng/ml, Peprotech, 200-06), IL-12 (20 ng/ml, Peprotech, 200-12), CGS21680 (10μM, MCE, HY13201A), SCH442416 (10μM, Tocris, 2463), etomoxir (5 μM, Selleck, S8244), forskolin (30μM, Sigma, 344270), IVA337 (20 μM, Selleck, S8770) and 666 −15 (0.1 μM, MCE, HY101120).

    Techniques: Expressing, Western Blot, Quantitative RT-PCR, Staining, Incubation, Control

    Fig. 6 A2A regulates CPT1A expression via p-CREB/CREB pathway. (A) Immunoblot analysis of p-CREB and CREB in dermal fibroblasts treated with TGF-β, with or without SCH442416 (10μM), for 48 h. (B-C) Immunoblot analysis of p-CREB, CREB, fibronectin and CPT1A (B); and RT-qPCR analysis of COL1A1, FN1 and CPT1A (C) in dermal fibroblasts pretreated with or without forskolin (30μM, 30 min), followed by stimulation with or without TGF-β for 48 h. (D-E) Im munoblot analysis of p-CREB, CREB, fibronectin and CPT1A (D); and RT-qPCR analysis of COL1A1, FN1 and CPT1A (E) in dermal fibroblasts pretreated with or without forskolin, followed by stimulation with or without TGF-β and SCH442416 (10μM) for 48 h. (F-G) Immunoblot analysis of p-CREB, CREB, fibronectin and CPT1A (F), and RT-qPCR analysis of COL1A1, FN1 and CPT1A (G) in dermal fibroblasts treated with TGF-β, CGS21680 (10μM), and 666 − 15 (0.1μM) for 48 h. RT-qPCR results were normalized against GAPDH. Error bars represent mean +/- SD range. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001; HC, healthy control

    Journal: Cell communication and signaling : CCS

    Article Title: Inhibition of adenosine/A2A receptor signaling suppresses dermal fibrosis by enhancing fatty acid oxidation.

    doi: 10.1186/s12964-025-02210-2

    Figure Lengend Snippet: Fig. 6 A2A regulates CPT1A expression via p-CREB/CREB pathway. (A) Immunoblot analysis of p-CREB and CREB in dermal fibroblasts treated with TGF-β, with or without SCH442416 (10μM), for 48 h. (B-C) Immunoblot analysis of p-CREB, CREB, fibronectin and CPT1A (B); and RT-qPCR analysis of COL1A1, FN1 and CPT1A (C) in dermal fibroblasts pretreated with or without forskolin (30μM, 30 min), followed by stimulation with or without TGF-β for 48 h. (D-E) Im munoblot analysis of p-CREB, CREB, fibronectin and CPT1A (D); and RT-qPCR analysis of COL1A1, FN1 and CPT1A (E) in dermal fibroblasts pretreated with or without forskolin, followed by stimulation with or without TGF-β and SCH442416 (10μM) for 48 h. (F-G) Immunoblot analysis of p-CREB, CREB, fibronectin and CPT1A (F), and RT-qPCR analysis of COL1A1, FN1 and CPT1A (G) in dermal fibroblasts treated with TGF-β, CGS21680 (10μM), and 666 − 15 (0.1μM) for 48 h. RT-qPCR results were normalized against GAPDH. Error bars represent mean +/- SD range. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001; HC, healthy control

    Article Snippet: For primary dermal fibroblasts treatment, cells were first starved in serum-free medium containing 0.1% FBS for 16 h, then treated with the following reagents as specified in each experiment, unless stated otherwise: TGF-β (10ng/ml, Peprotech, 100 −21), IL-1β (20 ng/ml, Peprotech, 200-01B), IL-4 (20 ng/ml, Peprotech, 200-04), IL-6 (20 ng/ml, Peprotech, 200-06), IL-12 (20 ng/ml, Peprotech, 200-12), CGS21680 (10μM, MCE, HY13201A), SCH442416 (10μM, Tocris, 2463), etomoxir (5 μM, Selleck, S8244), forskolin (30μM, Sigma, 344270), IVA337 (20 μM, Selleck, S8770) and 666 −15 (0.1 μM, MCE, HY101120).

    Techniques: Expressing, Western Blot, Quantitative RT-PCR, Control

    Schedule of experiment and scoring. A Schematic diagram of the experimental procedure. B Survival curve. C HE staining and Safranin O-fast green staining in each group. D Histological score changes in the L5-6 intervertebral disk. Data represented mean ± SD (n = 4). E BBB scores. Data represented mean ± SD.* P < 0.05 versus S group, † P < 0.05 versus M group, ‡ P < 0.05 versus CGS-21680 group. S, sham operation group; M, IL-1β-induced IDD model group; CGS-21680, A 2A R agonist CGS-21680 group; SCH442416, A 2A R antagonist SCH442416 group

    Journal: European Journal of Medical Research

    Article Title: A 2A R regulate inflammation through PKA/NF-κB signaling pathways in intervertebral disc degeneration

    doi: 10.1186/s40001-024-02028-7

    Figure Lengend Snippet: Schedule of experiment and scoring. A Schematic diagram of the experimental procedure. B Survival curve. C HE staining and Safranin O-fast green staining in each group. D Histological score changes in the L5-6 intervertebral disk. Data represented mean ± SD (n = 4). E BBB scores. Data represented mean ± SD.* P < 0.05 versus S group, † P < 0.05 versus M group, ‡ P < 0.05 versus CGS-21680 group. S, sham operation group; M, IL-1β-induced IDD model group; CGS-21680, A 2A R agonist CGS-21680 group; SCH442416, A 2A R antagonist SCH442416 group

    Article Snippet: Then, rats in CGS group received 50 μl (0.1 mg/kg, HY-13201A, Med Chem Express, Beijing, China) CGS-21680 injection [ ], and the rats in SCH group also received 50 μl (0.35 mg/kg, HY-103169, Med Chem Express, Beijing, China) SCH442416 injection [ ].

    Techniques: Staining

    A 2A R expression in rat IDD model. A Immunofluorescence staining images of A 2A R of NP cells and the drawing of partial enlargement in box (positive expression indicated with the yellow arrows). B RT-PCR and C Western blot were used to detect the expression level of A 2A R in four groups. Data represented mean ± SD. Scale bars = 50 μm. * P < 0.05 versus S group, † P < 0.05 versus M group, ‡ P < 0.05 versus CGS-21680 group. S, sham operation group; M, IL-1β-induced IDD model group; CGS-21680, A 2A R agonist CGS-21680 group; SCH442416, A 2A R antagonist SCH442416 group

    Journal: European Journal of Medical Research

    Article Title: A 2A R regulate inflammation through PKA/NF-κB signaling pathways in intervertebral disc degeneration

    doi: 10.1186/s40001-024-02028-7

    Figure Lengend Snippet: A 2A R expression in rat IDD model. A Immunofluorescence staining images of A 2A R of NP cells and the drawing of partial enlargement in box (positive expression indicated with the yellow arrows). B RT-PCR and C Western blot were used to detect the expression level of A 2A R in four groups. Data represented mean ± SD. Scale bars = 50 μm. * P < 0.05 versus S group, † P < 0.05 versus M group, ‡ P < 0.05 versus CGS-21680 group. S, sham operation group; M, IL-1β-induced IDD model group; CGS-21680, A 2A R agonist CGS-21680 group; SCH442416, A 2A R antagonist SCH442416 group

    Article Snippet: Then, rats in CGS group received 50 μl (0.1 mg/kg, HY-13201A, Med Chem Express, Beijing, China) CGS-21680 injection [ ], and the rats in SCH group also received 50 μl (0.35 mg/kg, HY-103169, Med Chem Express, Beijing, China) SCH442416 injection [ ].

    Techniques: Expressing, Immunofluorescence, Staining, Reverse Transcription Polymerase Chain Reaction, Western Blot

    Effects of A 2A R on the PKA/NF-κB pathway. A , B cAMP level was detected in the plasma and intervertebral disc tissues by ELISA. C RT-PCR results of PKA mRNA. D Images of PKA in each group with immunofluorescence staining in four groups and the drawing of partial enlargement in box (positive expression indicated with the yellow arrows). E – I Western-blot results of PKA, CREB and NF-κB in four groups. ( H , J , K ) RT-PCR results of CREB, NF-κB and NLRP3 mRNA. Scale bars = 50 μm. Data represented mean ± SD. Scale bars = 200 μm.* P < 0.05 versus S group, † P < 0.05 versus M group, ‡ P < 0.05 versus CGS-21680 group. S, sham operation group; M, IL-1β-induced IDD model group; CGS-21680, A 2A R agonist CGS-21680 group; SCH442416, A 2A R antagonist SCH442416 group

    Journal: European Journal of Medical Research

    Article Title: A 2A R regulate inflammation through PKA/NF-κB signaling pathways in intervertebral disc degeneration

    doi: 10.1186/s40001-024-02028-7

    Figure Lengend Snippet: Effects of A 2A R on the PKA/NF-κB pathway. A , B cAMP level was detected in the plasma and intervertebral disc tissues by ELISA. C RT-PCR results of PKA mRNA. D Images of PKA in each group with immunofluorescence staining in four groups and the drawing of partial enlargement in box (positive expression indicated with the yellow arrows). E – I Western-blot results of PKA, CREB and NF-κB in four groups. ( H , J , K ) RT-PCR results of CREB, NF-κB and NLRP3 mRNA. Scale bars = 50 μm. Data represented mean ± SD. Scale bars = 200 μm.* P < 0.05 versus S group, † P < 0.05 versus M group, ‡ P < 0.05 versus CGS-21680 group. S, sham operation group; M, IL-1β-induced IDD model group; CGS-21680, A 2A R agonist CGS-21680 group; SCH442416, A 2A R antagonist SCH442416 group

    Article Snippet: Then, rats in CGS group received 50 μl (0.1 mg/kg, HY-13201A, Med Chem Express, Beijing, China) CGS-21680 injection [ ], and the rats in SCH group also received 50 μl (0.35 mg/kg, HY-103169, Med Chem Express, Beijing, China) SCH442416 injection [ ].

    Techniques: Enzyme-linked Immunosorbent Assay, Reverse Transcription Polymerase Chain Reaction, Immunofluorescence, Staining, Expressing, Western Blot

    Effects of A 2A R on the inflammatory cytokines. A , B TNF-α and D , E IL-6 expression in the plasma and intervertebral disc tissues by ELISA. C , F RT-PCR results of TNF-α and IL-6 mRNA level. G – I Western-blot results of TNF-α and IL-6 protein in four groups. Data represented mean ± SD. Scale. * P < 0.05 versus S group, † P < 0.05 versus M group, ‡ P < 0.05 versus CGS-21680 group. S, sham operation group; M, IL-1β-induced IDD model group; CGS-21680, A 2A R agonist CGS-21680 group; SCH442416, A 2A R antagonist SCH442416 group

    Journal: European Journal of Medical Research

    Article Title: A 2A R regulate inflammation through PKA/NF-κB signaling pathways in intervertebral disc degeneration

    doi: 10.1186/s40001-024-02028-7

    Figure Lengend Snippet: Effects of A 2A R on the inflammatory cytokines. A , B TNF-α and D , E IL-6 expression in the plasma and intervertebral disc tissues by ELISA. C , F RT-PCR results of TNF-α and IL-6 mRNA level. G – I Western-blot results of TNF-α and IL-6 protein in four groups. Data represented mean ± SD. Scale. * P < 0.05 versus S group, † P < 0.05 versus M group, ‡ P < 0.05 versus CGS-21680 group. S, sham operation group; M, IL-1β-induced IDD model group; CGS-21680, A 2A R agonist CGS-21680 group; SCH442416, A 2A R antagonist SCH442416 group

    Article Snippet: Then, rats in CGS group received 50 μl (0.1 mg/kg, HY-13201A, Med Chem Express, Beijing, China) CGS-21680 injection [ ], and the rats in SCH group also received 50 μl (0.35 mg/kg, HY-103169, Med Chem Express, Beijing, China) SCH442416 injection [ ].

    Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Reverse Transcription Polymerase Chain Reaction, Western Blot

    Effect of A 2A R up-regulation on the expression of matrix metalloproteinase and type II collagen. A images of MMP3 in each group with immunofluorescence staining and and the drawing of partial enlargement in box (positive expression indicated with the yellow arrows) (Scale bars = 50 μm). B MMP3 and type II collagen levels were detected by western-blot. C , D Immunohistochemistry results of type II collagen in each group (Scale bars = 50 μm). Data represented mean ± SD.* P < 0.05 versus S group, † P < 0.05 versus M group, ‡ P < 0.05 versus CGS-21680 group. S, sham operation group; M, IL-1β-induced IDD model group; CGS-21680, A 2A R agonist CGS-21680 group; SCH442416, A 2A R antagonist SCH442416 group

    Journal: European Journal of Medical Research

    Article Title: A 2A R regulate inflammation through PKA/NF-κB signaling pathways in intervertebral disc degeneration

    doi: 10.1186/s40001-024-02028-7

    Figure Lengend Snippet: Effect of A 2A R up-regulation on the expression of matrix metalloproteinase and type II collagen. A images of MMP3 in each group with immunofluorescence staining and and the drawing of partial enlargement in box (positive expression indicated with the yellow arrows) (Scale bars = 50 μm). B MMP3 and type II collagen levels were detected by western-blot. C , D Immunohistochemistry results of type II collagen in each group (Scale bars = 50 μm). Data represented mean ± SD.* P < 0.05 versus S group, † P < 0.05 versus M group, ‡ P < 0.05 versus CGS-21680 group. S, sham operation group; M, IL-1β-induced IDD model group; CGS-21680, A 2A R agonist CGS-21680 group; SCH442416, A 2A R antagonist SCH442416 group

    Article Snippet: Then, rats in CGS group received 50 μl (0.1 mg/kg, HY-13201A, Med Chem Express, Beijing, China) CGS-21680 injection [ ], and the rats in SCH group also received 50 μl (0.35 mg/kg, HY-103169, Med Chem Express, Beijing, China) SCH442416 injection [ ].

    Techniques: Expressing, Immunofluorescence, Staining, Western Blot, Immunohistochemistry